top of page
< Back

Vorapaxar


Mechanism of action:

Vorapaxar is a protease-activated receptor-1 antagonist. Vorapaxar selectively antagonizes protease-activated receptor-1, blocking platelet activation initiated by the binding of thrombin to this receptor.

Reference(s):

1. Ghosal A et al. (2011). Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 


2. Lhermusier T et al. (2015). Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor. Am J Cardiol.

bottom of page